Research programme: anti-CD137 monoclonal antibodies - GTC Biotherapeutics
Alternative Names: Anti-4-1BB monoclonal antibodies - GTC; anti-CD137 monoclonal antibodies research programme - GTC BiotherapeuticsLatest Information Update: 04 Nov 2017
At a glance
- Originator Mayo Clinic
- Developer Mayo Clinic; rEVO Biologics
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders; Cancer
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies